5th July 2019 - Takeda Ireland, a subsidiary of Takeda Pharmaceutical Company Ltd, has officially opened a new cutting-edge manufacturing facility at its site at Grange Castle.
Marking the event, Minister for Employment Affairs and Social Protection, Regina Doherty, Takeda Pharmaceutical CEO Christophe Weber, H.E. Mrs. Mari Miyoshi, Japanese Ambassador to Ireland and Mary Buckley, Executive Director, IDA Ireland, joined 200 guests and staff for the opening celebration.
Takeda has created this high containment, state of the art production facility dedicated to the manufacturing of their oncology treatment. Construction of the plant began in June 2017 and was managed by Project Management Group. A total of 40 jobs will be created at the site. The plant is the first Active Pharmaceutical Ingredient (API) manufacturing operation to be located outside of Japan for Takeda and houses all steps of the production process including API, drug product and primary and secondary packaging for supply to global markets. The Takeda Grange Castle plant currently employs over 80 people, all of whom are trained in the latest manufacturing techniques, to ensure operational excellence.
Commenting on the opening event, Takeda Pharmaceutical CEO Christophe Weber said:
“I am delighted to be in Ireland for the official opening of our manufacturing site in Grange Castle. We have built up a strong foundation in Ireland over the past 17 years, and this new plant in Grange Castle is an important strategic site for us, as it is not only the first overseas manufacturing centre for APIs outside of Japan, but it houses all the steps of the production process. We are excited to take this next step and continue to deliver our medicines to patients around the world and concentrate our efforts on breakthrough innovations. I would like to thank our employees and stakeholders, as well as the IDA, for their support throughout the entire process.”
Commenting on the opening event, Mary Buckley, Executive Director, IDA Ireland said: “Manufacturing excellence in pharmaceuticals is a hallmark of Ireland's success in the sector. This innovative manufacturing site not only highlights Takeda’s commitment to Ireland, it also showcases how competitive Ireland is for global enterprise and investment. I wish Takeda continued success and on behalf of IDA Ireland offer our ongoing support.”
Minister for Employment Affairs and Social Protection, Regina Doherty TD said: “I am delighted to see Takeda expanding in Ireland. I know from their investment in their facility in Dunboyne, in my local constituency, that they are a great employer and a significant player in the global pharmaceutical sector. This state of the art manufacturing facility at Grange Castle is a great vote of confidence in Ireland and a very welcome development.”
In honour of the Japanese origins of the company and their continued investment in Ireland, Ambassador of Japan to Ireland, H.E. Mrs. Mari Miyoshi, unveiled a symbolic wooden sun dial at the event. Guests in attendance also had the opportunity to engage with interactive booths which highlight the innovative technology of Takeda.
In addition to their oncology treatments, Takeda Ireland produces APIs for the treatment of Diabetes, Oncology, Insomnia, Weight loss, Acid related disease, Bipolar disorder and Hypertension.
In addition to the grand opening, Takeda also used the opportunity to introduce another project in Grange Castle to the public. The company is investing about 30 million Euro into a regenerative medicine facility at its site in Grange Castle, which will be the first commercial scale cell therapy production facility in Ireland. This innovative facility will cover all steps of the cell therapy production process from receipt of donor material to fill finish, packaging and shipment off site to the patient.
About Takeda Pharmaceutical Company:
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. Approximately 55,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.
Across Ireland, Takeda has commercial operations, corporate services and three manufacturing facilities in Bray, Dunboyne and Grange Castle.
For more information, visit: https://www.takeda.com/en-ie.
The drug information contained herein is intended to disclose Takeda's corporate information. Nothing contained herein should be considered a solicitation, promotion or indication for any prescription drug including the ones under development.